A comparison of gene expression profiles between primary human AML cells and therapy-related AML cells

Cited 0 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorY H Kim-
dc.contributor.authorH S Kim-
dc.contributor.authorJ Hwang-
dc.contributor.authorJ Lee-
dc.contributor.authorS Kim-
dc.contributor.authorS Y Park-
dc.contributor.authorKyu Tae Chang-
dc.contributor.authorK S Kim-
dc.contributor.authorZ Y Ryoo-
dc.contributor.authorS Lee-
dc.date.accessioned2017-04-19T09:14:34Z-
dc.date.available2017-04-19T09:14:34Z-
dc.date.issued2008-
dc.identifier.issn1976-9148-
dc.identifier.uri10.4062/biomolther.2008.16.4.431ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/9110-
dc.description.abstractTo identify genes whose expression correlated with biological features of therapy-related AML (t-AML), we analyzed the expression profiles of de novo AML t(9;11) and t-AML t(9;11) bone marrow samples using previously published SAGE data. Three-hundred twenty-nine transcripts that satisfied statistical (P<0.05) and magnitude-of-change (≥ 4-fold) criteria were identified as differentially expressed between de novo AML t(9;11) and t-AML t(9;11) cells. of these transcripts, 301 (91%) matched known genes or ESTs and were classified according to functional categories (http://david.abcc.ncifcrf.gov/). The majority of differentially expressed genes in t-AML t(9;11) were involved in the regulation of biological and metabolic processes. Especially prominent among these were genes related to immune and drug responses. These results establish a framework for developing new drugs for the treatment of t-AML.-
dc.publisherKorea Soc-Assoc-Inst-
dc.titleA comparison of gene expression profiles between primary human AML cells and therapy-related AML cells-
dc.title.alternativeA comparison of gene expression profiles between primary human AML cells and therapy-related AML cells-
dc.typeArticle-
dc.citation.titleBiomolecules & Therapeutics-
dc.citation.number4-
dc.citation.endPage436-
dc.citation.startPage431-
dc.citation.volume16-
dc.contributor.affiliatedAuthorKyu Tae Chang-
dc.contributor.alternativeName김영훈-
dc.contributor.alternativeName김형수-
dc.contributor.alternativeName황준모-
dc.contributor.alternativeName이진석-
dc.contributor.alternativeName김성건-
dc.contributor.alternativeName박소영-
dc.contributor.alternativeName장규태-
dc.contributor.alternativeName김길수-
dc.contributor.alternativeName류재영-
dc.contributor.alternativeName이상규-
dc.identifier.bibliographicCitationBiomolecules & Therapeutics, vol. 16, no. 4, pp. 431-436-
dc.identifier.doi10.4062/biomolther.2008.16.4.431-
dc.subject.keywordGene expression-
dc.subject.keywordSAGE-
dc.subject.keywordTherapy-related AML-
dc.subject.localGene Expression-
dc.subject.localGene expression-
dc.subject.localgene expression-
dc.subject.localSAGE-
dc.subject.localTherapy-related AML-
dc.description.journalClassY-
Appears in Collections:
1. Journal Articles > Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.